<p>对于初学者来说，购买一家能够向投资者讲述好故事的公司似乎是个不错的主意（也是一个令人兴奋的前景），即使它目前缺乏收入和利润的业绩记录。不幸的是，这些高风险投资往往几乎没有回报的可能性，许多投资者为此付出了代价以吸取教训。一个亏损的公司尚未通过盈利证明自己，最终外部资本的流入可能会枯竭。</p>
<p>如果这种类型的公司不符合你的风格，而你更喜欢那些能够产生收入甚至盈利的公司，那么你可能会对 <strong>Royalty Pharma</strong>（NASDAQ:RPRX）感兴趣。现在并不是说这家公司提供了最佳的投资机会，但盈利能力是商业成功的关键组成部分。</p>
<p>特朗普承诺要 “释放” 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<h2>Royalty Pharma 的每股收益正在增长</h2>
<p>市场在短期内是一个投票机，但在长期内是一个称重机，因此你可以预期股价最终会跟随每股收益（EPS）的结果。因此，经验丰富的投资者在进行投资研究时会密切关注公司的 EPS。令人印象深刻的是，Royalty Pharma 在过去三年中每年复合增长了 22% 的 EPS。如果公司能够维持这种增长，我们预计股东会感到满意。</p>
<p>查看息税前利润（EBIT）利润率以及收入增长，通常对了解公司增长的质量很有帮助。尽管收入数据相对平稳，股东们会高兴地看到 EBIT 利润率在过去 12 个月中从 42% 增长到 84%。这值得高兴。</p>
<p>下图显示了公司底线和顶线随时间的变化。点击图表查看具体数字。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/669151476-earnings-and-revenue-history-1-dark-2/1748702901632?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/669151476-earnings-and-revenue-history-1-dark-2/1748702901632"/></p>
<p>NasdaqGS:RPRX 每股收益和收入历史 2025 年 5 月 31 日</p>
<p>查看我们对 Royalty Pharma 的最新分析</p>
<p>虽然我们生活在当下，但毫无疑问，未来在投资决策过程中最为重要。那么为什么不查看这个描绘 Royalty Pharma 未来 EPS 估计的互动图表呢？</p>
<h2>Royalty Pharma 的内部人士与所有股东的利益一致吗？</h2>
<p>我们不期望看到内部人士拥有像 Royalty Pharma 这样一家价值 180 亿美元的公司的大比例股份。但由于他们对公司的投资，令人欣慰的是，仍然有激励措施使他们的行为与股东一致。我们注意到，他们在公司的可观股份价值达 17 亿美元。投资者会欣赏管理层在这方面的投入，因为这显示了他们对公司未来的承诺。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.simplywall.st/news/1748322310639-Valuation_banner.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.simplywall.st/news/1748322310639-Valuation_banner.png"/></p>
<h2>Royalty Pharma 值得在你的观察名单上占有一席之地吗？</h2>
<p>你不能否认 Royalty Pharma 以非常令人印象深刻的速度增长了每股收益。这是有吸引力的。此外，高水平的内部持股令人印象深刻，表明管理层重视 EPS 增长，并对 Royalty Pharma 的持续实力充满信心。快速增长和自信的内部人士应该足以促使进一步研究，因此似乎这是一个值得关注的好股票。不要忘记，仍然可能存在风险。例如，我们已经识别出 <strong>Royalty Pharma 的 3 个警告信号</strong>，你应该注意。</p>
<p>尽管 Royalty Pharma 看起来确实不错，但如果内部人士购买股票，可能会吸引更多投资者。如果你喜欢看到公司有更多的投入，那么请查看这份精心挑选的公司名单，这些公司不仅拥有强劲的增长，还得到了强大的内部支持。</p>
<p><em>请注意，本文讨论的内部交易是指在相关司法管辖区内可报告的交易。</em></p>

RPRX

<p>Royalty Pharma（纳斯达克代码：RPRX）展现了令人印象深刻的增长，过去三年每股收益（EPS）年均增长 22%。尽管收入持平，息税前利润（EBIT）利润率已从 42% 提高至 84%。价值 17 亿美元的内部持股表明管理层对公司未来的承诺。虽然 Royalty Pharma 提供了一个强劲的投资机会，但潜在投资者应注意三个警示信号。总体而言，公司的增长和内部一致性使其成为值得关注的股票，尽管仍存在风险</p>

<p>For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.</p>
<div class="lb-trans"><p>对于初学者来说，购买一家能够向投资者讲述好故事的公司似乎是个不错的主意（也是一个令人兴奋的前景），即使它目前缺乏收入和利润的业绩记录。不幸的是，这些高风险投资往往几乎没有回报的可能性，许多投资者为此付出了代价以吸取教训。一个亏损的公司尚未通过盈利证明自己，最终外部资本的流入可能会枯竭。</p>
</div><p>If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in <strong>Royalty Pharma</strong> (NASDAQ:RPRX). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.</p>
<div class="lb-trans"><p>如果这种类型的公司不符合你的风格，而你更喜欢那些能够产生收入甚至盈利的公司，那么你可能会对 <strong>Royalty Pharma</strong>（NASDAQ:RPRX）感兴趣。现在并不是说这家公司提供了最佳的投资机会，但盈利能力是商业成功的关键组成部分。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要 “释放” 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><h2>Royalty Pharma's Earnings Per Share Are Growing</h2>
<div class="lb-trans"><h2>Royalty Pharma 的每股收益正在增长</h2>
</div><p>The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Impressively, Royalty Pharma has grown EPS by 22% per year, compound, in the last three years. If the company can sustain that sort of growth, we'd expect shareholders to come away satisfied.</p>
<div class="lb-trans"><p>市场在短期内是一个投票机，但在长期内是一个称重机，因此你可以预期股价最终会跟随每股收益（EPS）的结果。因此，经验丰富的投资者在进行投资研究时会密切关注公司的 EPS。令人印象深刻的是，Royalty Pharma 在过去三年中每年复合增长了 22% 的 EPS。如果公司能够维持这种增长，我们预计股东会感到满意。</p>
</div><p>It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. Despite the relatively flat revenue figures, shareholders will be pleased to see EBIT margins have grown from 42% to 84% in the last 12 months. That's something to smile about.</p>
<div class="lb-trans"><p>查看息税前利润（EBIT）利润率以及收入增长，通常对了解公司增长的质量很有帮助。尽管收入数据相对平稳，股东们会高兴地看到 EBIT 利润率在过去 12 个月中从 42% 增长到 84%。这值得高兴。</p>
</div><p>The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.</p>
<div class="lb-trans"><p>下图显示了公司底线和顶线随时间的变化。点击图表查看具体数字。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/669151476-earnings-and-revenue-history-1-dark-2/1748702901632" alt="" original-src="https://images.simplywall.st/asset/chart/669151476-earnings-and-revenue-history-1-dark-2/1748702901632"/></p>
<p>NasdaqGS:RPRX Earnings and Revenue History May 31st 2025</p>
<div class="lb-trans"><p>NasdaqGS:RPRX 每股收益和收入历史 2025 年 5 月 31 日</p>
</div><p>See our latest analysis for Royalty Pharma</p>
<div class="lb-trans"><p>查看我们对 Royalty Pharma 的最新分析</p>
</div><p>While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for Royalty Pharma?</p>
<div class="lb-trans"><p>虽然我们生活在当下，但毫无疑问，未来在投资决策过程中最为重要。那么为什么不查看这个描绘 Royalty Pharma 未来 EPS 估计的互动图表呢？</p>
</div><h2>Are Royalty Pharma Insiders Aligned With All Shareholders?</h2>
<div class="lb-trans"><h2>Royalty Pharma 的内部人士与所有股东的利益一致吗？</h2>
</div><p>We would not expect to see insiders owning a large percentage of a US$18b company like Royalty Pharma. But thanks to their investment in the company, it's pleasing to see that there are still incentives to align their actions with the shareholders. We note that their impressive stake in the company is worth US$1.7b. Investors will appreciate management having this amount of skin in the game as it shows their commitment to the company's future.</p>
<div class="lb-trans"><p>我们不期望看到内部人士拥有像 Royalty Pharma 这样一家价值 180 亿美元的公司的大比例股份。但由于他们对公司的投资，令人欣慰的是，仍然有激励措施使他们的行为与股东一致。我们注意到，他们在公司的可观股份价值达 17 亿美元。投资者会欣赏管理层在这方面的投入，因为这显示了他们对公司未来的承诺。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.simplywall.st/news/1748322310639-Valuation_banner.png" alt="" original-src="https://media.simplywall.st/news/1748322310639-Valuation_banner.png"/></p>
<h2>Does Royalty Pharma Deserve A Spot On Your Watchlist?</h2>
<div class="lb-trans"><h2>Royalty Pharma 值得在你的观察名单上占有一席之地吗？</h2>
</div><p>You can't deny that Royalty Pharma has grown its earnings per share at a very impressive rate. That's attractive. Further, the high level of insider ownership is impressive and suggests that the management appreciates the EPS growth and has faith in Royalty Pharma's continuing strength. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. Don't forget that there may still be risks. For instance, we've identified <strong>3 warning signs for Royalty Pharma</strong> that you should be aware of.</p>
<div class="lb-trans"><p>你不能否认 Royalty Pharma 以非常令人印象深刻的速度增长了每股收益。这是有吸引力的。此外，高水平的内部持股令人印象深刻，表明管理层重视 EPS 增长，并对 Royalty Pharma 的持续实力充满信心。快速增长和自信的内部人士应该足以促使进一步研究，因此似乎这是一个值得关注的好股票。不要忘记，仍然可能存在风险。例如，我们已经识别出 <strong>Royalty Pharma 的 3 个警告信号</strong>，你应该注意。</p>
</div><p>Although Royalty Pharma certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.</p>
<div class="lb-trans"><p>尽管 Royalty Pharma 看起来确实不错，但如果内部人士购买股票，可能会吸引更多投资者。如果你喜欢看到公司有更多的投入，那么请查看这份精心挑选的公司名单，这些公司不仅拥有强劲的增长，还得到了强大的内部支持。</p>
</div><p><em>Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.</em></p>
<div class="lb-trans"><p><em>请注意，本文讨论的内部交易是指在相关司法管辖区内可报告的交易。</em></p>
</div>

以下是我们认为 Royalty Pharma（NASDAQ:RPRX）非常值得关注的原因